Loading...
XLON
HIK
Market cap4.69bUSD
Dec 05, Last price  
1,594.00GBP
1D
0.25%
1Q
-7.33%
Jan 2017
-15.80%
IPO
465.25%
Name

Hikma Pharmaceuticals PLC

Chart & Performance

D1W1MN
XLON:HIK chart
P/E
13.07
P/S
1.50
EPS
1.63
Div Yield, %
3.88%
Shrs. gr., 5y
-1.66%
Rev. gr., 5y
7.22%
Revenues
3.13b
+8.77%
262,215,000317,022,000448,796,000580,656,000636,884,000730,936,000918,025,0001,108,721,0001,365,000,0001,489,000,0001,440,000,0001,950,000,0001,936,000,0002,070,000,0002,207,000,0002,341,000,0002,553,000,0002,517,000,0002,875,000,0003,127,000,000
Net income
359m
+88.95%
43,867,00054,522,00062,576,00057,125,00077,683,00098,849,00080,107,000100,320,000212,000,000278,000,000252,000,000155,000,000-843,000,000282,000,000486,000,000431,000,000421,000,000188,000,000190,000,000359,000,000
CFO
564m
-7.24%
32,713,00029,992,00043,117,00057,872,000105,518,000138,786,000102,639,000182,161,000337,000,000425,000,000366,000,000293,000,000443,000,000430,000,000472,000,000464,000,000638,000,000530,000,000608,000,000564,000,000
Dividend
Aug 15, 202424.73536 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
IPO date
Nov 01, 2005
Employees
8,700
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT